Increase Success in Drug Discovery While Reducing Time and Cost with RepliGut®
ABOUT US
Altis Biosystems has created a next-generation in vitro platform that reduces the time and cost of developing safer, more effective drugs.
By replicating native human biology, the intestinal stem cell platform produces more accurate and reproducible data for better clinical trial performance and reduces the need for animal testing.
PLATFORM
The RepliGut® Platform
The RepliGut® model is a unique, stem cell derived platform that recreates the human small intestine and colonic epithelium for more biologically relevant screening of compounds, disease modeling, and microbiome research.
With a scalable platform, actionable data, high throughput screening to test compounds, and an unrivaled biobank of ethically derived donor intestinal cells, the RepliGut® model is the future of in vitro testing during drug development.
SERVICES
The RepliGut® is a reproducible and scalable platform that is suitable for studying many aspects of drug disposition including toxicity, metabolism, drug absorption, and efficacy.
Intestinal Barrier Function
Maintains barrier integrity with high TEER values
Inflammatory Response
Comprised of polarized intestinal cells grown on transwells
GI Toxicity
Screen compounds for drug-induced GI toxicity early
Intestinal Drug Disposition
Developed to replace Caco-2 cells (cancer cells) and animals